Jump to content

Property:Drop-out reasons

From CAMIH

This is a property of type Text.

Showing 20 pages using this property.
A
B
Lost to follow-up (n=7) Discontinued intervention (n=34) - Capsule side-effects (n=6) - Other medical problems (n=8) - Participation too troublesome (n=13) - Wanted to take vitamin E (n=5) - Physician requested to stop (n=2)  +
Lost to follow-up (n=4) Discontinued intervention (n=36) - Capsule side-effects (n=6) - Difficulty swallowing capsules (n=3) - Other medical problems (n=9) - Participation too troublesome (n=13) - Wanted to take vitamin E (n=2) - Physician requested to stop (n=3)  +
Lost to follow-up (n=7) Discontinued intervention (n=34) - Capsule side-effects (n=6) - Other medical problems (n=8) - Participation too troublesome (n=13) - Wanted to take vitamin E (n=5) - Physician requested to stop (n=2)  +
Lost to follow-up (n=4) Discontinued intervention (n=36) - Capsule side-effects (n=6) - Difficulty swallowing capsules (n=3) - Other medical problems (n=9) - Participation too troublesome (n=13) - Wanted to take vitamin E (n=2) - Physician requested to stop (n=3)  +
Lost to follow-up (n=7) Discontinued intervention (n=34) - Capsule side-effects (n=6) - Other medical problems (n=8) - Participation too troublesome (n=13) - Wanted to take vitamin E (n=5) - Physician requested to stop (n=2)  +
Lost to follow-up (n=4) Discontinued intervention (n=36) - Capsule side-effects (n=6) - Difficulty swallowing capsules (n=3) - Other medical problems (n=9) - Participation too troublesome (n=13) - Wanted to take vitamin E (n=2) - Physician requested to stop (n=3)  +
Not arm specified: Adverse effects (n = 25, 13 with ginger and 12 with placebo), withdrawal consent (n = 24), lost to follow-up (n = 1); protocol violations (n = 2), and other (n = 45; namely, changes to chemotherapy regimen (n = 5 for ginger versus n = 6 for placebo), patient’s decision (14 versus 7), concomitant medications (n = 1 for ginger), logistical problems (n = 2 for each group), health status (n = 3 for ginger), intolerance (n = 5 for ginger).  +
Not arm specified: Adverse effects (n = 25, 13 with ginger and 12 with placebo), withdrawal consent (n = 24), lost to follow-up (n = 1); protocol violations (n = 2), and other (n = 45; namely, changes to chemotherapy regimen (n = 5 for ginger versus n = 6 for placebo), patient’s decision (14 versus 7), concomitant medications (n = 1 for ginger), logistical problems (n = 2 for each group), health status (n = 3 for ginger), intolerance (n = 5 for ginger).  +